{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T23:10:59Z","timestamp":1793661059860,"version":"4.5.1"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Commission","doi-asserted-by":"publisher","award":["00179906"],"award-info":[{"award-number":["00179906"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.ejmech.2022.114580","type":"journal-article","created":{"date-parts":[[2022,6,30]],"date-time":"2022-06-30T02:04:58Z","timestamp":1656554698000},"page":"114580","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":6,"special_numbering":"C","title":["7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties"],"prefix":"10.1016","volume":"240","author":[{"given":"Lukas","family":"Gorecki","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darina","family":"Muthna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Merdita","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Andrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomas","family":"Kucera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Radim","family":"Havelek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lubica","family":"Muckova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tereza","family":"Kobrlova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiri","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Petr","family":"Krupa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lukas","family":"Prchal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ondrej","family":"Soukup","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaroslav","family":"Roh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5370-2290","authenticated-orcid":false,"given":"Martina","family":"Rezacova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6977-7596","authenticated-orcid":false,"given":"Jan","family":"Korabecny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2022.114580_bib1","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.3390\/cancers12082098","article-title":"DNA damage-inducing anticancer therapies: from global to precision damage","volume":"12","author":"Reuvers","year":"2020","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114580_bib2","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1016\/j.cell.2011.02.013","article-title":"Hallmarks of cancer: the next generation","volume":"144","author":"Hanahan","year":"2011","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114580_bib3","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1016\/j.molcel.2010.09.019","article-title":"The DNA damage response: making it safe to play with knives","volume":"40","author":"Ciccia","year":"2010","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114580_bib4","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/nature03097","article-title":"Cell-cycle checkpoints and cancer","volume":"432","author":"Kastan","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114580_bib5","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1038\/nrc3342","article-title":"The effects of deregulated DNA damage signalling on cancer chemotherapy response and resistance","volume":"12","author":"Bouwman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114580_bib6","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.molonc.2014.10.013","article-title":"Untangling the ATR-CHEK1 network for prognostication, prediction and therapeutic target validation in breast cancer","volume":"9","author":"Abdel-Fatah","year":"2015","journal-title":"Mol. Oncol."},{"key":"10.1016\/j.ejmech.2022.114580_bib7","doi-asserted-by":"crossref","first-page":"1070","DOI":"10.1016\/j.molcel.2020.04.035","article-title":"Biomarker-guided development of DNA repair inhibitors","volume":"78","author":"Cleary","year":"2020","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114580_bib8","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1038\/nature03094","article-title":"G1 cell-cycle control and cancer","volume":"432","author":"Massagu\u00e9","year":"2004","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2022.114580_bib9","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/j.molcel.2017.05.001","article-title":"Replication catastrophe: when a checkpoint fails because of exhaustion","volume":"66","author":"Toledo","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114580_bib10","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers13040795","article-title":"Clinical candidates targeting the ATR\u2013CHK1\u2013WEE1 Axis in cancer","volume":"13","author":"Gorecki","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.ejmech.2022.114580_bib11","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pharmthera.2016.01.014","article-title":"Synthetic lethal approaches for assessing combinatorial efficacy of chemotherapeutic drugs","volume":"162","author":"Jackson","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114580_bib12","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.molcel.2017.05.015","article-title":"ATM, ATR, and DNA-PK: the trinity at the heart of the DNA damage response","volume":"66","author":"Blackford","year":"2017","journal-title":"Mol. Cell."},{"key":"10.1016\/j.ejmech.2022.114580_bib13","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1038\/nrm.2017.67","article-title":"The essential kinase ATR: ensuring faithful duplication of a challenging genome","volume":"18","author":"Saldivar","year":"2017","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ejmech.2022.114580_bib14","doi-asserted-by":"crossref","first-page":"3474","DOI":"10.1038\/onc.2014.276","article-title":"ATR inhibition preferentially targets homologous recombination-deficient tumor cells","volume":"34","author":"Krajewska","year":"2015","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114580_bib15","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.4161\/cbt.21093","article-title":"The novel ATR inhibitor VE-821 increases sensitivity of pancreatic cancer cells to radiation and chemotherapy","volume":"13","author":"Prevo","year":"2012","journal-title":"Cancer Biol. Ther."},{"key":"10.1016\/j.ejmech.2022.114580_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.pharmthera.2020.107518","article-title":"Discovery of ATR kinase inhibitor berzosertib (VX-970, M6620): clinical candidate for cancer therapy","author":"Gorecki","year":"2020","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114580_bib17","doi-asserted-by":"crossref","first-page":"5547","DOI":"10.1021\/acs.jmedchem.9b00426","volume":"62","author":"Knegtel","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib18","doi-asserted-by":"crossref","first-page":"2320","DOI":"10.1021\/jm101488z","article-title":"Discovery of potent and selective inhibitors of ataxia telangiectasia mutated and Rad3 related (ATR) protein kinase as potential anticancer agents","volume":"54","author":"Charrier","year":"2011","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib19","doi-asserted-by":"crossref","first-page":"9889","DOI":"10.1021\/acs.jmedchem.8b01187","article-title":"Discovery and characterization of AZD6738, a potent inhibitor of ataxia telangiectasia mutated and Rad3 related (ATR) kinase with application as an anticancer agent","volume":"61","author":"Foote","year":"2018","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib20","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1021\/jm301859s","article-title":"Discovery of 4-{4-[(3R)-3-Methylmorpholin-4-yl]-6-[1-(methylsulfonyl)cyclopropyl]pyrimidin-2-yl}-1H-indole (AZ20): a potent and selective inhibitor of ATR protein kinase with monotherapy in vivo antitumor activity","volume":"56","author":"Foote","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib21","doi-asserted-by":"crossref","first-page":"7293","DOI":"10.1021\/acs.jmedchem.0c00369","article-title":"Damage incorporated: discovery of the potent, highly selective, orally available ATR inhibitor BAY 1895344 with favorable pharmacokinetic properties and promising efficacy in monotherapy and in combination treatments in preclinical tumor models","volume":"63","author":"L\u00fccking","year":"2020","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib22","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2019-369","article-title":"Abstract 369: antitumor activity of M4344, a potent and selective ATR inhibitor, in monotherapy and combination therapy","volume":"79","author":"Zenke","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114580_bib23","doi-asserted-by":"crossref","DOI":"10.1158\/1538-7445.AM2017-983","article-title":"Abstract 983: identification of potent, highly selective and orally available ATR inhibitor BAY 1895344 with favorable PK properties and promising efficacy in monotherapy and combination in preclinical tumor models","volume":"77","author":"Luecking","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114580_bib24","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1021\/acsmedchemlett.1c00034","article-title":"1,2,4-Oxadiazole-Bearing pyrazoles as metabolically stable modulators of store-operated calcium entry","volume":"12","author":"Aprile","year":"2021","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2022.114580_bib25","doi-asserted-by":"crossref","first-page":"756","DOI":"10.1002\/humu.22556","article-title":"Analysis of TP53 mutation status in human cancer cell lines: a reassessment","volume":"35","author":"Leroy","year":"2014","journal-title":"Hum. Mutat."},{"key":"10.1016\/j.ejmech.2022.114580_bib26","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1158\/0008-5472.CAN-16-2179","article-title":"Recommended guidelines for validation, quality control, and reporting of TP53 variants in clinical practice","volume":"77","author":"Leroy","year":"2017","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114580_bib27","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.ejphar.2014.07.025","article-title":"Cisplatin in cancer therapy: molecular mechanisms of action","volume":"740","author":"Dasari","year":"2014","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.ejmech.2022.114580_bib28","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1124\/pr.111.005637","article-title":"Cisplatin resistance: a cellular self-defense mechanism resulting from multiple epigenetic and genetic changes","volume":"64","author":"Shen","year":"2012","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ejmech.2022.114580_bib29","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/onc.2011.384","article-title":"Molecular mechanisms of cisplatin resistance","volume":"31","author":"Galluzzi","year":"2012","journal-title":"Oncogene"},{"key":"10.1016\/j.ejmech.2022.114580_bib30","doi-asserted-by":"crossref","DOI":"10.1007\/s11060-021-03789-5","article-title":"US Food and Drug Administration regulatory updates in neuro-oncology","author":"Mehta","year":"2021","journal-title":"J. Neuro Oncol."},{"key":"10.1016\/j.ejmech.2022.114580_bib31","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/S2213-8587(21)00120-0","article-title":"Pralsetinib for patients with advanced or metastatic RET-altered thyroid cancer (ARROW): a multi-cohort, open-label, registrational, phase 1\/2 study","volume":"9","author":"Subbiah","year":"2021","journal-title":"Lancet Diabetes Endocrinol."},{"key":"10.1016\/j.ejmech.2022.114580_bib32","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2021.113495","article-title":"Aurora kinase inhibitors as potential anticancer agents: recent advances","volume":"221","author":"Pradhan","year":"2021","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib33","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1038\/nrc2964","article-title":"Shared and separate functions of polo-like kinases and aurora kinases in cancer","volume":"10","author":"Lens","year":"2010","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ejmech.2022.114580_bib34","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcyt.2021.05.008","article-title":"Anti-tumor effects of vascular endothelial growth factor\/vascular endothelial growth factor receptor binding domain-modified chimeric antigen receptor T cells","author":"Xing","year":"2021","journal-title":"Cytotherapy"},{"key":"10.1016\/j.ejmech.2022.114580_bib35","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.3390\/cells10051222","article-title":"Anti-vascular endothelial growth factor C antibodies efficiently inhibit the growth of experimental clear cell renal cell carcinomas","volume":"10","author":"Dumond","year":"2021","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2022.114580_bib36","doi-asserted-by":"crossref","first-page":"2650","DOI":"10.1158\/0008-5472.CAN-05-1843","article-title":"Inhibition of VEGFR-3 activation with the antagonistic antibody more potently suppresses lymph node and distant metastases than inactivation of VEGFR-2","volume":"66","author":"Roberts","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ejmech.2022.114580_bib37","doi-asserted-by":"crossref","first-page":"2666","DOI":"10.1056\/NEJMoa072113","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ejmech.2022.114580_bib38","doi-asserted-by":"crossref","first-page":"12022","DOI":"10.1021\/acs.jmedchem.1c00678","article-title":"Discovery, synthesis, and evaluation of highly selective vascular endothelial growth factor receptor 3 (VEGFR3) inhibitor for the potential treatment of metastatic triple-negative breast cancer","volume":"64","author":"Li","year":"2021","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib39","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0140-6736(15)01088-0","article-title":"Antiangiogenic therapy in oncology: current status and future directions","volume":"388","author":"Jayson","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.ejmech.2022.114580_bib40","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/cr.2017.158","article-title":"Cryo-EM structure of human ATR-ATRIP complex","volume":"28","author":"Rao","year":"2018","journal-title":"Cell Res."},{"key":"10.1016\/j.ejmech.2022.114580_bib41","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.pharmthera.2017.10.017","article-title":"Glioblastoma and chemoresistance to alkylating agents: involvement of apoptosis, autophagy, and unfolded protein response","volume":"184","author":"Hombach-Klonisch","year":"2018","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114580_bib42","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.pharmthera.2015.05.005","article-title":"Glioblastoma multiforme: pathogenesis and treatment","volume":"152","author":"Alifieris","year":"2015","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2022.114580_bib43","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1016\/j.cell.2013.09.034","article-title":"The somatic genomic landscape of glioblastoma","volume":"155","author":"Brennan","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.ejmech.2022.114580_bib45","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/1758-2946-3-33","article-title":"Open Babel: an open chemical toolbox","volume":"3","author":"O'Boyle","year":"2011","journal-title":"J. Cheminf."},{"key":"10.1016\/j.ejmech.2022.114580_bib46","doi-asserted-by":"crossref","first-page":"1605","DOI":"10.1002\/jcc.20084","article-title":"UCSF Chimera--a visualization system for exploratory research and analysis","volume":"25","author":"Pettersen","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib47","doi-asserted-by":"crossref","first-page":"2785","DOI":"10.1002\/jcc.21256","article-title":"AutoDock4 and AutoDockTools4: automated docking with selective receptor flexibility","volume":"30","author":"Morris","year":"2009","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib48","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/jcc.21334","article-title":"AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization, and multithreading","volume":"31","author":"Trott","year":"2010","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib49","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.jmgm.2005.12.005","article-title":"Automatic atom type and bond type perception in molecular mechanical calculations","volume":"25","author":"Wang","year":"2006","journal-title":"J. Mol. Graph. Model."},{"key":"10.1016\/j.ejmech.2022.114580_bib50","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1002\/jcc.20035","article-title":"Development and testing of a general amber force field","volume":"25","author":"Wang","year":"2004","journal-title":"J. Comput. Chem."},{"key":"10.1016\/j.ejmech.2022.114580_bib51","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.softx.2015.06.001","article-title":"GROMACS: high performance molecular simulations through multi-level parallelism from laptops to supercomputers","volume":"1\u20132","author":"Abraham","year":"2015","journal-title":"SoftwareX"},{"key":"10.1016\/j.ejmech.2022.114580_bib52","doi-asserted-by":"crossref","first-page":"4630","DOI":"10.3390\/ijms20184630","article-title":"The evaluation of glioblastoma cell dissociation and its influence on its behavior","volume":"20","author":"Skarkova","year":"2019","journal-title":"Int. J. Mol. Sci."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004822?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523422004822?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T14:41:12Z","timestamp":1759329672000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523422004822"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":51,"alternative-id":["S0223523422004822"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114580","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"7-Azaindole, 2,7-diazaindole, and 1H-pyrazole as core structures for novel anticancer agents with potential chemosensitizing properties","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2022.114580","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"114580"}}